Du är här


Ganeden Biotech: New United States Patent Protects Probiotic Innovation in All Coffee, Tea, and Cereal

Ganeden Biotech issued patent covers all
Bacillus coagulans
including GanedenBC30

CLEVELAND, OH (April 29, 2014)
-- Ganeden Biotech, a recognized world leader in the manufacturing and
marketing of probiotics, today announced the issuance of a United States
patent that covers the use of allBacillus coagulans
in all coffee, tea and cereal.

The issuance of patent #US 8,697,055 B2 protects the use of allBacillus
probiotic strains including GanedenBC30
in coffee, tea and cereal applications. "Our patent attorneys at Mintz Levin
continue to provide superior legal counsel that strengthens our market
position," said David Keller, Ganeden Biotech VP of Scientific Operations.

The probiotic industry is growing rapidly, with no indication that it will be
slowing down anytime soon; by 2015 the market is expected to reach $31.1
billion globally, with about 90% of that from the sale of functional foods
and beverages. In addition, consumer awareness continues to increase with
over 80% of consumers associating probiotics with a health benefit. Ganeden
Biotech's goal is to make probiotics available in every-day food so that
consumers don't have to take another pill. Coffee, tea and cereal are a big
part of that.

Spore forming probiotic organisms such as GanedenBC30
are the only probiotics that have the ability to withstand harsh manufacturing
processes, especially those required to make hot tea, coffee and cereal. The
effectiveness of these organisms can be linked to its naturally occurring
layer of organic material (spore), which protects the genetic core of the
bacteria throughout the manufacturing process and the transit in to the gut.
Non-spore forming probiotics, such asLactobacillus
, are unable to form this protective layer, making them much more vulnerable
to manufacturing conditions.

"This patent goes a long way toward supporting our partners in their quest to
launch new brands, and revolutionize existing ones," said Andy Lefkowitz, CEO
of Ganeden Biotech. "When combined with the FDA's No Objection letter on GRAS
(safety), 17 studies published in peer reviewed journals, over 100 patents
issued around the world and the pending issuance of the first monograph by
the USP, we have again demonstrated our commitment to science-based probiotic


About Ganeden Biotech

Ganeden Biotech is at the forefront of probiotic research and product
development with an extensive library of published studies and more than 100
patents for probiotic technologies in the food, beverage, animal health, and
now personal care ingredients markets. Ganeden is best known for GanedenBC30
(Bacillus coagulans
GBI-30, 6086), its patented, FDA GRAS, highly stable probiotic ingredient.
Ganeden's newest ingredient, Bonicel, is the first science-backed,
probiotic-derived, personal care ingredient shown to dramatically reduce
signs of aging. For more information about Ganeden Biotech and licensing
opportunities visit GanedenBiotech.com.

About GanedenBC30

Introducing GanedenBC30
® (Bacillus coagulans GBI-30, 6086), Ganeden Biotech's patented probiotic
ingredient that can be found in more than 100 leading food, beverage and
companion animal products throughout the world. Unlike most other probiotic
strains, GanedenBC30
is a spore-former which makes it highly stable and allows it remain viable
through most manufacturing processes, three years of shelf life and the low
pH of stomach acid. The efficacy of GanedenBC30
is backed by 17 published studies showing digestive and immune support and
has an exceptional safety record with FDA GRAS status from the United States
FDA. It can be formulated into virtually any product that is baked, boiled,
frozen or squeezed..including all hot or refrigerated beverages! For more
information, please visitGanedenBiotech.comorGanedenBC30.com.

Media Contact:

Julie Lebowitz

Public Relations Coordinator



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ganeden Biotech via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.